Trabectedin as a chemotherapy option for patients with brca deficiency

Highlights • We sought if BRCA deficiencies are associated with clinical responses to trabectedin. • BRCA genes are an important predictive indicator of sensitivity to trabectedin. • Improved response to trabectedin is a hallmark of BRCA1/2-mutated carriers. • Stratification based on BRCA mutations...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer treatment reviews 2016-11, Vol.50, p.175-182
Hauptverfasser:	Monk, Bradley J, Lorusso, Domenica, Italiano, Antoine, Kaye, Stan B, Aracil, Miguel, Tanović, Adnan, D’Incalci, Maurizio
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents, Alkylating - administration & dosage Antineoplastic Agents, Alkylating - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use BRCA BRCA1 Protein - deficiency BRCA2 Protein - deficiency Breast Breast Neoplasms - drug therapy Breast Neoplasms - genetics Dioxoles - administration & dosage Dioxoles - therapeutic use Doxorubicin - administration & dosage Doxorubicin - analogs & derivatives Female Genes, BRCA1 Genes, BRCA2 Hematology, Oncology and Palliative Medicine Hereditary Breast and Ovarian Cancer Syndrome - drug therapy Hereditary Breast and Ovarian Cancer Syndrome - genetics Humans Mutations Ovarian cancer Ovarian Neoplasms - drug therapy Ovarian Neoplasms - genetics Polyethylene Glycols - administration & dosage Sarcoma Sarcoma - drug therapy Sarcoma - genetics Tetrahydroisoquinolines - administration & dosage Tetrahydroisoquinolines - therapeutic use Trabectedin Yondelis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • We sought if BRCA deficiencies are associated with clinical responses to trabectedin. • BRCA genes are an important predictive indicator of sensitivity to trabectedin. • Improved response to trabectedin is a hallmark of BRCA1/2-mutated carriers. • Stratification based on BRCA mutations should become standard in upcoming trials.
ISSN:	0305-7372 1532-1967
DOI:	10.1016/j.ctrv.2016.09.009